Keytruda-Inlyta combo under Priority Review for first-line RCC

Merck & Co. Inc. (NYSE:MRK) said FDA accepted and granted Priority Review to its sBLA for Keytruda pembrolizumab plus Inlyta axitinib

Read the full 219 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE